Progress on the application of growth factor-related drugs in ophthalmology

WANG, Xiaojie; HUI, Qi; Jin, Zi; RAO, Fengqin; YU, Bingjie; Jin, Lei; BANDA, Joshua; LI, Xiaokun

doi:10.3724/zdxbyxb-2022-0075

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main strategy in stage 1 NK treatment is to improve epithelial quality and stability, accelerate corneal healing, and prevent stromal involvement ( 9 ). NK therapy includes a diverse spectrum such as nerve growth factor (NGF) eye drops, neuropeptides (substance P), surgical therapy, and autologous blood-based eye drops ( 48 , 58 , 59 ). OXERVATE ® (cenegermin-bkbj), an FDA-approved topical recombinant human nerve growth factor, was reported as an efficient therapy in moderate to severe NK that can lead to significant improvement in corneal sensation and complete resolution of epithelial defect ( 60 – 62 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Sabater

Ghalibafan

Osei

et al. 2023

Preprint

View full text Add to dashboard Cite

Background/Aims: Neurotrophic keratitis (NK) is a neurodegenerative disease that can lead to corneal hypoesthesia, decreased tear production, and epitheliopathy. Based on the severity of ocular surface damage, NK is classified into 3 stages. Stage 1 NK is characterized by superficial punctate keratopathy, tear film instability, and reduced corneal sensation. The therapeutic efficacy of PRGF eye drops for NK stages 2 and 3 has been previously reported. In this study, we evaluated the efficacy and safety of autologous PRGF eye drops in improving corneal sensitivity and other ocular surface clinical signs in patients with stage 1 NK. Methods: Retrospective chart review Results: 26 eyes of 15 stage 1 NK patients (seven males, eight females), aged 76.3 ± 12.1 years, were included in the study. The mean treatment duration was 2 ± 1.8 months. With PRGF treatment, corneal sensitivity increased from 2.8 to 4.5 cm in 53.8% (14/26) (p < 0.01), TBUT increased from 3.6 to 5.0 s in 69.2% (18/26) (p < 0.01), and Schirmer score increased from 13.7 to 16.8 mm in 80.7% (21/26) of treated eyes (p < 0.01). Similarly, an improvement in corneal staining (punctate epithelial erosions) and MMP-9 levels was seen in 80.7% (n = 21) and 65.4% (n = 17) of treated eyes, respectively. BCVA improvement was seen in 26.9% of treated eyes (n = 7). Conclusions:This study demonstrates the effective role of PRGF therapy in recovering corneal sensation and tear film function and in the healing of corneal erosions in stage 1 NK patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Sabater

Ghalibafan

Osei

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

NGF-releasing Prussian blue nanoparticles for nerve injury repair of lumbar disc herniation

Tang,

Sun,

et al. 2024

Front. Chem.

View full text Add to dashboard Cite

IntroductionCompression of the nerve root by a lumbar disc herniation can cause radiating pain in the lower limbs, and the nerve root decompression treatment may leave some patients with motor dysfunction and reduced sensory function. Studies have shown that nerve growth factor (NGF) can promote nerve growth and repair, but high doses, long duration, and immune response have become bottlenecks of its clinical application.MethodsTo overcome this obstacle, we developed Prussian blue (PBs) nanoparticles with the bio-delivery function and antioxidant effects of nanoenzymes. NGF was conjugated to the surface of PBs nanoparticles (PBs-NGF), which can be directly delivered to nerve cells.ResultsThe results showed that free PBs showed great advantages in scavenging oxygen free radicals and antioxidants, while PBs-NGF showed good biocompatibility. At the cellular level, cell proliferation assay and fluorescence microscopy analysis confirmed that PBs-NGF significantly promoted the proliferation, differentiation, and neurite outgrowth of neuron-like PC12 cells compared with free NGF. In a nerve root compression (NRC) rat model, behavioral observations (paw withdrawal threshold, PWT, and paw withdrawal latency, PWL) confirmed that PBs-NGF eased the pain caused by nerve root compression. H&E staining showed that PBs-NGF could significantly reduce the inflammatory infiltration of nerve roots, and ELISA results showed that the concentrations of inflammatory markers (IL-6, IL-1β, and TNF-α) were also significantly reduced.ConclusionIn summary, the developed functional nanoplatform provides a basis for the clinical application of NGF in lumbar nerve root injury with disc herniation compression and a new treatment strategy for patients.

show abstract

Progress on the application of growth factor-related drugs in ophthalmology

Cited by 2 publications

References 45 publications

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis

NGF-releasing Prussian blue nanoparticles for nerve injury repair of lumbar disc herniation

Contact Info

Product

Resources

About